06.09.26 -- CDMO Capacity Crunch: Are Biotechs Wasting Time On The Wrong CDMO?

Thorough characterization is key to unlocking the potential of antibody-based therapeutics. Leveraging a CDMO's extensive capabilities and expertise can allow you to navigate the landscape.

Biologics manufacturing is evolving through smarter fill technologies, onshoring, advanced automation, and data driven processes that improve efficiency, reduce risk, and protect product value.

Developing robust, scalable microbial fermentation depends on optimizing growth and expression phases through efficient oxygen transfer, fine-tuning of nutrient delivery, and induction of protein expression.

Process development and optimization enabled efficient scale‑up of a complex lung cancer therapy, improving yields, reducing costs, and supporting rapid clinical and commercial progress.

Explore how data‑driven collaboration and animal‑origin‑free media strategies can reduce variability, improve cell culture performance, and support consistent, cost‑effective bioprocessing at scale.

Integrated real-time visibility transforms outsourced gene therapy manufacturing from fragmented, reactive coordination into proactive execution, enabling faster decisions and timeline confidence.

Leverage a platform-based analytical development strategy to accelerate ADC IND readiness through early CQA identification, reduced development risk, and streamlined progression.

Learn how an integrated developability and immunosafety toolbox can help de-risk multi-specific antibody development, improve candidate selection, and accelerate complex biologics toward the clinic.